Takeda’s zasocitinib bests Sotyktu in phase III psoriasis trial

AI Briefing

• – • Takeda's zasocitinib shows superiority over Sotyktu in phase III psoriasis trial results.
• – • Zasocitinib demonstrated significant improvement in psoriasis symptoms and quality of life in trial participants.
• – • Takeda is expected to submit regulatory applications for zasocitinib in the coming months.